I am interrupting the reviews of the AACR meeting to inform you of a very important piece of news.

Men with advanced prostate cancer which is castrate resistant and who have 2 blaistic bone metastases may now have access to Alpharadin even though the FDA has not yet approved it in the United States!

It has been announced that Radium-223 Chloride (Alpharadin) will becoming available for Early/Expanded Access.

Initially, it will be available in New Orleans, LA, but future potential sites will probably include sites in AZ, CA, FL, MA, MO, NV, PA, SC, TX, WV – check link below):

The trial is structured with no placebo and no cost for the Alpharadin. You should check with trial site for any other costs which you might be responsible to pay.

Basic Eligibility Criteria:

• CRPC/HRPC – on hormone therapy with progressive disease

• At least 2 bone metastases – blastic (sclerotic), not lytic

• Some amount of pain/bone pain (must be taking daily meds – even if it’s Tylenol)

• No mets to lung, liver, or brain

• HGB 10.0 or higher

• Previously treated with Taxotere (or have refused Taxotere – patient’s choice)

• 4 weeks since chemo and No chemo currently planned

• No abiraterone (Zytiga) while on Alpharadin – previous Zytiga is alright

• No previous extensive radiation to bone (> 25% of bone marrow), and no previous Quadramet or Strontium 89

If you think you fit the above criteria, contact either Patrick Cotogno, or Oliver Sartor MD for further screening at:

Tulane University
1415 Tulane Ave. HC-62
New Orleans, LA 70112
Phone: (504) 988-2735
Principle Investigator: osartor@tulane.edu
Study Coordinator: pcotogno@tulane.edu

* For more on Alpharadin (Radium 223), read my other posts at:



Joel T Nowak, M.A., M.S.W.